Top Gainers & Losers: NTPC jumps, Sun Pharma falls the most among blue-chip stocks

Top Gainers & Losers: Indian equity benchmarks Sensex and Nifty50 finished largely unchanged with a negative bias on Tuesday. Globally, investors stayed on the back foot ahead of the release of the minutes of the FOMC's first policy review of 2023. The Sensex shed 18.8 points to settle at 60,672.7 and the Nifty slipped 17.9 points to end at 17,826.7.

Barring the Nifty FMCG and the Nifty Financial Services, all of NSE's sectoral indices closed in the red. In the Nifty50 basket, NTPC, Britannia and Tata Steel were the top gainers, whereas Adani Enterprises, Apollo Hospitals and Coal India were the top losers.

Here are some of the blue-chip stocks that made the biggest moves on February 21:

NTPC

NTPC gained three per cent to end at Rs 173.4 apiece on NSE — emerging the top gainer in both the Sensex and Nifty50 universes.

Image Source: Stockedge

Nuvama Institutional Equities maintained a ‘buy’ rating on the NTPC stock with a target of Rs 200 per share, implying upside potential of 16 per cent.

Britannia Industries

Britannia Industries rose more than one per cent to Rs 4,506 apiece. The FMCG major's stock was among the top blue-chip gainers of the day.

Image Source: Stockedge

"We continue to like the management’s narrative of driving top- and bottom-line growth by strengthening power brands via innovation, relaunches and premiumisation," Phillip Capital Analyst Vishal Gutka said.

The brokerage maintained a ‘buy’ rating on Britannia with a target of Rs 5,400 apiece, implying upside potential of 20 per cent.

Sun Pharma

Sun Pharma shares climbed up about 1.5 per cent to end at Rs 971.4 apiece on BSE, and were among the top laggards in the 30-scrip basket.

Image Source: Stockedge

“We remain positive on Sun Pharma on the back of multiple triggers such as the ramp-up of branded and specialty business in the US, continued growth in the India business, the potential inorganic opportunity due to a strong balance sheet,” Nirmal Bang Analyst Mitesh Shah said.

The brokerage assigned a ‘buy’ rating on Sun Pharma with a target price of Rs 1,202 per share.

Catch latest stock market updates here. For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com.